Rationale: Cardiovascular disease is a common comorbidity in patients with chronic obstructive pulmonary disease. Although b-blockers can be used safely in patients with chronic obstructive pulmonary disease, concerns remain regarding safety and efficacy interactions in patients using concomitant inhaled long-acting b-agonists.
Inhaled type 2 b-adrenoreceptor agonists are bronchodilators with proven efficacy in patients with chronic obstructive pulmonary disease (COPD) (1) . b 1 -Selective adrenoreceptor antagonists (b-blocker therapies) are effective antianginal (2) and antihypertensive (3) therapies, and they are also associated with secondary preventive and mortality benefits in patients with a prior myocardial infarction (4) or left ventricular systolic dysfunction (5) . Although modern inhaled b 2 -agonists and oral b 1 -antagonists are designed to be highly selective for their respective receptors, there remains concern about cross-reactivity between receptors and the potential for pharmacological interactions that might adversely affect their safety and efficacy, particularly at high doses often required in clinical practice (6) (7) (8) .
Despite concerns that b-blockers may adversely affect lung function, particularly those b-blockers that are not cardioselective (9) , numerous studies have suggested that cardioselective drugs are safe and well tolerated in patients with COPD (10, 11) . Indeed, they do not affect the change in lung function over time (12) , and they may in fact reduce the risk of exacerbations and all-cause mortality (13) (14) (15) ), a question being tested in a large placebo-controlled clinical trial (16) . However, no studies have adequately examined the impact of b-blocker use on the short-and long-term responses to inhaled long-acting b-agonist treatment, although reviews have highlighted the need for these data (7, 17) .
The researchers in the SUMMIT study (Study to Understand Mortality and Morbidity in COPD) assessed the effects of an inhaled corticosteroid (fluticasone furoate) and a long-acting b-agonist (vilanterol), alone or in combination, in patients with moderate COPD and either preexisting cardiovascular disease or a heightened risk of cardiovascular disease (18) . Although there was no effect on all-cause mortality, all active treatments reduced the risk of COPD exacerbations compared with placebo, and both of the corticosteroid-containing arms demonstrated reduction in the rate of decline of forced expiratory volume in 1 second (FEV 1 ) (18) . There was also no evidence that vilanterol was associated with adverse cardiovascular events (19) . However, given the high prevalence of cardiovascular disease and the frequent use of b-blockers among participants, the SUMMIT study provides a unique opportunity to examine whether the drugs impacted the therapeutic effects of vilanterol and fluticasone. We hypothesized that b-blocker use at baseline would not impact the associations between vilanterol, fluticasone, or their combination and lung function, exacerbations, cardiovascular events, or mortality.
Methods
The study design, analytical approach, and primary results have been published previously (18, 20 Participants were categorized according to b-blocker use at baseline, regardless of subsequent changes in therapy during the course of the trial. Those receiving b-blockers were further subclassified according to whether they used a b 1 -selective or b-nonselective adrenoreceptor antagonist.
Outcomes reported in this paper are on-treatment and post-treatment all-cause mortality; on-treatment change from baseline in FEV 1 at 3 months (primary analysis), 6 months, and 12 months; on-treatment time to first adjudicated cardiovascular composite event; ontreatment revascularization or adjudicated cardiovascular composite event; and ontreatment time to first exacerbation of COPD. The 3-month time point for FEV 1 was chosen because any potential association between baseline b-blocker use and lung function would have been apparent by that time. The time-to-event endpoints were analyzed using data up to and including the common end date as per the overall analysis of these endpoints reported in the primary publication (18) .
Statistical Analysis
All analyses in this report were prespecified and based on the intention-to-treat efficacy population. Baseline characteristics were summarized using mean and SD values for continuous covariates or percentages for categorical covariates for participants receiving b-blocker therapy at study entry (baseline), those not receiving the therapy, and overall.
Post-bronchodilator FEV 1 was analyzed using a mixed effects repeated measures model adjusted for age, sex, and baseline post-bronchodilator FEV 1 (ml). This analysis included the covariates of treatment, visit, b-blocker use at study entry, and their twoand three-way interactions, as well as sex and the continuous covariates of age, baseline FEV 1 , and baseline FEV 1 3 visit interaction. The differences in adjusted mean change between placebo and treatment arms at 3, 6, and 12 months were assessed overall and within each b-blocker use group.
Cox proportional hazards analyses of time to first moderate or severe COPD exacerbation were performed. First, an unadjusted analysis was conducted, fitting a b-blocker use covariate in the placebo arm only, to compare participants receiving b-blockers with those who were not. This analysis was then adjusted for potential confounders of age, sex, ischemic heart disease indicator (if participants had a previous myocardial infarction or coronary artery bypass graft or percutaneous coronary intervention), vascular disease indicator (if participants had a previous cerebrovascular accident or transient ischemic attack or had previous surgery for or were receiving medication for carotid or aortofemoral vascular disease), prior medication for ventricular arrhythmia, congestive heart failure history, hypertension history, smoking status, cardiovascular entry criteria (aged 40 to ,60 yr with cardiovascular disease, or aged 60-80 yr with cardiovascular risk, or aged 60-80 yr with cardiovascular disease), region, body mass index (BMI), and the number of COPD exacerbations in the year before the study (none, one, or two or more). To assess the associations with treatment, an unadjusted Cox proportional hazards model was fitted, including treatment, b-blocker use at study entry, and b-blocker use 3 treatment interaction.
These survival analyses were repeated for cardiovascular composite event, revascularization or cardiovascular composite event, and all-cause mortality. Kaplan-Meier plots of time to first moderate or severe COPD exacerbation and ORIGINAL RESEARCH cardiovascular composite event were produced to illustrate the differences between treatments within b-blocker use subgroups. Kaplan-Meier plots for these endpoints were also created within b-blocker use subgroup subdivided by b 1 -selectivity (i.e., participants not receiving baseline b-blocker therapy vs. receiving baseline selective b 1 -blocker therapy vs. receiving baseline nonselective b-blocker therapy).
Results
Of the 16,485 SUMMIT participants, just under one-third (n = 5,159) were receiving oral b-blocker therapy at baseline. Of those subjects receiving b-blockers at baseline, 82% were receiving cardioselective b-blockers. Compared with participants not receiving b-blocker therapy, they had a higher BMI, had an increased prevalence of cardiovascular risk factors, and were more likely to have cardiovascular disease, especially ischemic heart disease ( Table 1) . Overall follow-up and treatment exposure were similar, regardless of b-blocker therapy use at baseline (mean treatment exposure, 1.6 yr up to the common end date).
Lung Function and Exacerbations of COPD
Baseline lung function was similar for those receiving b-blocker therapy and those who were not (mean FEV 1 , 60% of predicted) ( Table 1) . Presence or absence of b-blocker therapy at baseline was not associated with differences in the association between inhaled treatments compared with placebo and post-bronchodilator FEV 1 at 3 months (interaction P = 0.27), 6 months (interaction P = 0.14), or 12 months (interaction P = 0.33). The placebo-adjusted mean difference in post-bronchodilator FEV 1 at 3 months in the vilanterol-alone group was 58 ml (95% confidence interval [CI], 38-78) in those receiving baseline b-blocker therapy, and it was 51 ml (95% CI, 38-65) in those not receiving baseline b-blocker therapy. The placebo-adjusted mean difference in post-bronchodilator FEV 1 at 3 months in the fluticasone furoate/vilanterol combination group was 85 ml (95% CI, 65-105) in those receiving baseline b-blocker therapy, and it was 68 ml (95% CI, 54-82) in those not receiving baseline b-blocker therapy (Table 2) .
Similarly, there were no differences in the association between vilanterol-alone or fluticasone furoate/vilanterol combination therapy compared with placebo and post-bronchodilator FEV 1 at 6 months or 12 months between the two b-blocker groups.
There were similar percentages of participants with a history of previous COPD exacerbations in the year before the study in the b-blocker and no-b-blocker groups (Table 1) . After randomization, among those receiving placebo, moderate or severe exacerbations were equally as likely to have occurred in participants receiving b-blocker therapy (30.9%) as among those not receiving b-blocker therapy (29.2%) (unadjusted analysis hazard ratio [HR], 1.06; 95% CI, 0.94-1.19; P = 0.35). There were also no significant interactions with study treatment; that is, the association between study treatment and exacerbation risk was similar, regardless of b-blocker therapy (P = 0.18) (Table 3, Figure 1 ).
Cardiovascular Events and All-Cause Mortality
The time to first cardiovascular event was similar regardless of b-blocker therapy, and it was not associated with study treatment (Figure 2, Table 3 ). In the placebo group, the proportion of participants experiencing cardiovascular events appeared to be higher among participants receiving b-blocker therapy (4.8%) than among those not receiving b-blocker therapy (4.0%), although this difference was not statistically significant (HR, 1.21; 95% CI, 0.89-1.66; P = 0.23). The association was further attenuated toward the null after adjusting for potential confounders (HR, 0.96; 95% CI, 0.68-1.36; P = 0.82). There were also no interactions between study treatment and b-blocker therapy (P = 0.33) ( Table 3 ). In the placebo arm, there was a somewhat higher risk of cardiovascular events in those receiving b-blockers when revascularization was added to the primary composite cardiovascular event endpoint (6.9% vs. 4.7%) (unadjusted HR, 1.50; 95% CI, 1.14-1.96; P , 0.01). 
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All-cause mortality was similar regardless of b-blocker therapy. In the placebo group, there were no differences in the percentage of participants who died (6.3% with b-blocker therapy and 6.9% without b-blocker therapy; HR, 0.92; 95% CI, 0.71-1.19; P = 0.52). This was unchanged after adjusting for all potential confounders (HR, 0.94; 95% CI, 0.71-1.25; P = 0.67). Again, there were no interactions between study treatment and b-blocker therapy (P = 0.41) ( Table 3 ). Sensitivity analyses restricted to b 1 -selective agents yielded similar results for the risk of exacerbations, cardiovascular events, and mortality.
Discussion
We investigated the influence of baseline b-blocker therapy on the potential benefits and hazards of inhaled therapy in patients with moderate COPD and heightened cardiovascular risk. We have demonstrated that despite the increased cardiovascular risk profile of SUMMIT participants, study efficacy and safety outcomes were similar regardless of baseline b-blocker therapy. Specifically, b-blocker therapy was not associated with a detrimental effect on lung function or COPD exacerbations, and it did not appear to attenuate the treatment benefits associated with inhaled therapies 1 from baseline at 3 mo, ml (SE)
27 (5) 29 (5) 44 (5) 61 (5) Treatment difference from placebo (baseline to 3 mo), ml (95% CI) 36 (23-50) 51 (38-65) 68 (54-82)
b-blockers at baseline b-blocker therapy, n 1,280 1,330 1,246 1,303 Adjusted change in FEV 1 from baseline at 3 mo, ml (SE) 1 (7) 31 (7) 59 (7) 85 ( 
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including the b 2 -agonist vilanterol. Similarly, vilanterol was not associated with an excess of adverse cardiovascular events, and this was apparently unaffected by the presence or absence of baseline b-blocker therapy. SUMMIT was a major prospective trial of inhaled corticosteroid and long-acting b-agonist therapy (20) . It was distinguished by its large size and inclusion of patients with mild to moderate COPD who also had or were at risk for cardiovascular disease. As such, it provided an ideal platform with which to explore the potential mitigating effects of b-blocker therapy on the benefits and hazards of inhaled b 2 -agonist therapy.
We have demonstrated that vilanterol improved lung function regardless of baseline b-blocker therapy. Indeed, in contrast to participants in the Rotterdam study (21) , patients receiving b-blockers appeared to have similar lung function at enrollment and comparable increases in FEV 1 with vilanterol (alone and in combination with fluticasone furoate) versus placebo at 3, 6, and 12 months when compared with those not receiving b-blockers. These findings were consistent regardless of whether b-blocker therapy was b 1 selective or nonselective. Our observations are also consistent with previous studies suggesting that cardioselective b-blockers do not affect lung function or the response to b-agonists in the short term (10, 11) . These results extend those of Duffy and colleagues, who found no association between b-blocker use and the change in lung function over time in the National Institutes of Healthsponsored MACRO (Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations) and STATCOPE (Prospective Randomized PlaceboControlled Trial of Simvastatin in the Prevention of COPD Exacerbations) trials by showing that the long-term FEV 1 response to inhaled b-agonists was similarly unaffected (12) .
Though examination of the association between b-blockers and exacerbations was not our primary objective, we found no difference between patients receiving and not receiving b-blockers at baseline in this population with heightened cardiovascular risk. This contrasts with a number of prior observational studies suggesting protective effects (13, 15) , but it is again consistent with the data reported by Duffy and colleagues, who found no association between b-blocker use and exacerbation risk, regardless of the presence of cardiac comorbidities (12) , and it emphasizes the importance of ongoing randomized trials (16) . Similar to the trend for lung function, the benefit of vilanterol alone or in combination with fluticasone furoate was numerically better in patients receiving baseline b-blockers than in those not receiving b-blockers, although there were no statistically significant interactions between treatment and use of baseline b-blocker therapy.
Previous studies have suggested an increased cardiovascular risk associated with inhaled b-agonist therapies (6) . If this association were mediated through b 1 cross-reactivity and resultant cardiac toxicity, it would be hypothesized that patients in SUMMIT would have increased cardiovascular risk, especially in the absence of the protective effects of b-blocker therapy. We observed no such excess cardiovascular hazard in patients not receiving b-blocker therapy, with risk 
of an event being similar regardless of baseline therapy. This suggests that there is no major cardiovascular hazard of b 2 -agonist therapy in patients with COPD and heightened cardiovascular risk who are not receiving baseline b-blocker therapy. Again, this is borne out by previous meta-analyses of observational cohort studies (13, 22) .
The present analysis incorporates observational data within a randomized controlled trial. The use of baseline b-blocker therapy at study entry was not randomized, and changes in b-blocker use during the trial were not captured precisely. As such, it remains possible that our results could be affected by residual bias, including confounding by indication, and causal interactions between b-blocker use and the response to inhaled treatments cannot be determined. In addition, although compliance with the inhaled treatments was excellent (96 to 97% across treatment groups, regardless of whether the patient was receiving b-blockers at study entry), we do not know whether b-blockers were continued after enrollment or if patients were compliant. Patients in the SUMMIT study who were receiving b-blocker therapy had a higher cardiovascular risk profile, with two-to threefold higher percentages of previous ischemic heart disease, heart failure, and arrhythmia than those not receiving the drugs. As such, it is biologically quite plausible that they would be particularly sensitive to the potential hazards of b-agonists. However, we observed no differences in the risk of adverse cardiovascular events, regardless of baseline b-blocker therapy.
In conclusion, patients with COPD and heightened cardiovascular risk continue to receive respiratory benefit without an excess cardiovascular risk resulting from long-acting b-agonist therapy, regardless of baseline b-blocker therapy. We suggest that treatment decisions regarding the use of inhaled b-agonist therapy should not be influenced by the presence or absence of b-blocker therapy. Moreover, b-blocker therapy should be initiated in patients with COPD when there is a clear indication for therapy to prevent or treat cardiovascular disease. n ORIGINAL RESEARCH
